Preclinical and clinical stage biotechs have been the most impacted but also stand to gain the most after the economic downturn and subsequent recovery. 💰📈 Here, Justin Culbertson, CPA of RSM US LLP delves into how small to midsize pre-revenue biotechs have been specifically impacted and what this could mean for organizations that support them. #clinicaltrials #clinicalresearch #biotech
Clinical Leader’s Post
More Relevant Posts
-
It's often quoted that 80% of trials fail to enroll on time. Coupled with the fact that recruitment services are among the most frequently outsourced trial functions at 73%, it's clear that selecting an effective patient recruitment and retention partner is part of the challenge. We're excited to introduce a new solution! Join us August 7th at the Clinical Leader Solutions Expo: Patient Recruitment and Retention to watch industry-leading vendors share their capabilities and answer your questions to help aid you along your patient journey. Reserve your spot today: https://lnkd.in/eEnkg-kw
To view or add a comment, sign in
-
-
📢 Introducing the Clinical Leader Solutions Expo: Patient Recruitment & Retention, a free digital event for sponsors to hear from industry leaders and innovators aiding sponsors along the patient journey. From feasibility and site selection, through the recruitment and enrollment of patients, to the reimbursement and logistics services key to keeping them engaged, this interactive forum will allow these vendors to share their capabilities and answer your questions! Reserve your spot for the August 7th event: https://lnkd.in/emNG5pAX
To view or add a comment, sign in
-
-
June's Most Read Articles! View our top 5 insights in clinical research: https://lnkd.in/ecWUazJ3 Marjorie Zettler, PhD, MPH, Accutar Biotech | Kimberly Tableman, ESPERO | Donatella Ballerini | Laura Acosta, Anju Software | Julie Blasingim, Univo IRB
Best of June: Top 5 Insights in Clinical Research
clinicalleader.com
To view or add a comment, sign in
-
This guide provides 5 crucial recommendations to refine evaluation strategies and choose the right EDC solution for today's complex clinical data environment, optimizing data collection practices. https://lnkd.in/d3ek2nqB Source: Veeva Systems
To view or add a comment, sign in
-
-
In this week's issue, we'll explore what the FDA's critique of Lykos' MDMA studies means for the pursuit of psychedelic therapies, how SaaS technology can transform traditional listing reviews, strategies to increase enrollment of black women in trials, how a couple plans to revamp Poland's clinical trial system, and other popular insights! Abby Proch | ThoughtSphere | Dan Schell, Dr Hanna Preus MBA, FRQA, MICR, Dr Artur Preus, ICA / CAMS | Kianta Key | Advarra | Nael Abdelsamad, MD, MBA, FACHE | Crucial Data Solutions, Inc. | Aurea Flores, PhD, CCRP, CHRC, CHC, CHPC, RQAP-GCP, RPh | Veristat
Psychedelic Community's Reaction To FDA's Critique Of Lykos' MDMA Studies, 5 Strategies To Increase Enrollment Of Black Women In Trials, and More
Clinical Leader on LinkedIn
To view or add a comment, sign in
-
Check out part one of a two-part Q&A chief editor Dan Schell had with Nicole M. Palmer, MS about a variety of issues surrounding the trial master file (#TMF). In this part, she talks about the TMF Reference Model, moving to an eISF, and challenges with e-signatures: https://lnkd.in/evZW2w3k
To view or add a comment, sign in
-
-
The overload of technology for sponsored trial execution has left sites with less capacity to run trials. Join us to learn about One Home for Sites – the only vendor-neutral, sponsor-neutral platform that aggregates and connects the key systems and tasks a site needs to perform across all the clinical trials it is conducting. Remove the burdens and still gains the benefits! #OneHome #Clinical #clinicaltechnology
This content isn’t available here
Access this content and more in the LinkedIn app
To view or add a comment, sign in
-
The FDA has released a draft guidance, Data Integrity for In Vivo Bioavailability and Bioequivalence Studies. This article shares a concise summary. https://lnkd.in/etbeiFy4 By Susan Shockey, Clarkston Consulting
Quick Read: FDA's New Draft Guidance On Data Integrity For In Vivo BA/BE Studies
clinicalleader.com
To view or add a comment, sign in
-
Gain insights into how experts are handling regulatory changes, AI integration, and resource constraints in Trial Master File (#TMF) management through insights showcased at the recent Fierce TMF Summit. https://lnkd.in/et6ib2hb Source: Cencora | Pharma solutions
Key Trends And Hot Topics From The Fierce TMF Summit US
clinicalleader.com
To view or add a comment, sign in
-
Siteless #DCTs (decentralized trials) are rare, but Praxis Precision Medicines, Inc. is running one now for patients with essential tremor (ET). Marcio Souza, PharmD, the company’s president and CEO, talks about why they chose this model and the surprising speed at which it is progressing. https://lnkd.in/dAx3wTWi By Dan Schell, Chief Editor, Clinical Leader
Siteless DCTs Are Real … And Happening Now
clinicalleader.com
To view or add a comment, sign in
More from this author
-
Psychedelic Community's Reaction To FDA's Critique Of Lykos' MDMA Studies, 5 Strategies To Increase Enrollment Of Black Women In Trials, and More
Clinical Leader 3d -
The Secret Weapon of GCP Quality Assurance, Medical Device Trials vs. Drug Trials, and More
Clinical Leader 1w -
How IRB's Can Keep Up With The Clinical Trial Industry, Who The Top Performing CROs Are of 2024, and More
Clinical Leader 2w